Humiglim M 2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation of Humiglim M 2 ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is indicated for patients inadequately controlled on diet, exercise, and monotherapy with either agent. Humiglim M 2 should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels and renal function is recommended. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Humiglim M 2 Tablet SR offers an effective, convenient option for optimizing glycemic control in type 2 diabetes patients requiring dual therapy.